このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Repligen マネジメント
マネジメント 基準チェック /44
Repligen'sの CEO はTony Huntで、 May2015年に任命され、 の在任期間は 9.08年です。 の年間総報酬は$ 7.93Mで、 11.1%給与と88.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.23%を直接所有しており、その価値は$ 15.82M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と8.3年です。
主要情報
Tony Hunt
最高経営責任者
US$7.9m
報酬総額
| CEO給与比率 | 11.1% |
| CEO在任期間 | 9.1yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 3.9yrs |
| 取締役会の平均在任期間 | 8.3yrs |
経営陣の近況
Recent updates
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$8m | US$880k | US$42m |
| Sep 30 2023 | n/a | n/a | US$116m |
| Jun 30 2023 | n/a | n/a | US$138m |
| Mar 31 2023 | n/a | n/a | US$168m |
| Dec 31 2022 | US$8m | US$800k | US$186m |
| Sep 30 2022 | n/a | n/a | US$166m |
| Jun 30 2022 | n/a | n/a | US$159m |
| Mar 31 2022 | n/a | n/a | US$146m |
| Dec 31 2021 | US$8m | US$761k | US$128m |
| Sep 30 2021 | n/a | n/a | US$119m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$80m |
| Dec 31 2020 | US$5m | US$725k | US$60m |
| Sep 30 2020 | n/a | n/a | US$44m |
| Jun 30 2020 | n/a | n/a | US$31m |
| Mar 31 2020 | n/a | n/a | US$23m |
| Dec 31 2019 | US$4m | US$685k | US$21m |
| Sep 30 2019 | n/a | n/a | US$23m |
| Jun 30 2019 | n/a | n/a | US$27m |
| Mar 31 2019 | n/a | n/a | US$21m |
| Dec 31 2018 | US$14m | US$600k | US$17m |
| Sep 30 2018 | n/a | n/a | US$23m |
| Jun 30 2018 | n/a | n/a | US$23m |
| Mar 31 2018 | n/a | n/a | US$29m |
| Dec 31 2017 | US$3m | US$550k | US$28m |
報酬と市場: Tonyの 総報酬 ($USD 7.93M ) は、 US市場 ($USD 8.45M ) の同様の規模の企業の平均とほぼ同 じです。
報酬と収益: Tonyの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Tony Hunt (60 yo)
9.1yrs
在職期間
US$7,929,275
報酬
Mr. Anthony J. Hunt, also known as Tony, serves as Director at 908 Devices Inc. since March 2, 2022. He has been the Chief Executive Officer of Repligen Corporation since May 21, 2015 and served as its Pre...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 9.1yrs | US$7.93m | 0.23% $ 15.8m | |
| President & Chief Commercial Officer | less than a year | US$5.45m | データなし | |
| CFO & Chief Compliance Officer | less than a year | US$2.03m | データなし | |
| Chief Operating Officer | 4.3yrs | US$3.74m | 0.037% $ 2.6m | |
| Senior Vice President of Filtration & Chromatography | 3.9yrs | US$1.66m | 0.049% $ 3.4m | |
| Senior Vice President of Research & Development | 7.7yrs | US$1.66m | 0.031% $ 2.1m | |
| Chief Information Officer | no data | データなし | データなし | |
| Global Head of Investor Relations | no data | データなし | データなし | |
| General Counsel & Global Head of Legal | no data | データなし | データなし | |
| VP & Global Head of Sales | 1.7yrs | データなし | データなし | |
| Vice President of Human Resources | 1.4yrs | データなし | データなし | |
| Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics | 4.4yrs | データなし | データなし |
3.9yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: RGENの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 9.1yrs | US$7.93m | 0.23% $ 15.8m | |
| Independent Director | 8.7yrs | US$322.84k | 0.014% $ 942.9k | |
| Member of Scientific Advisory Board | 8.3yrs | データなし | データなし | |
| Independent Director | 1.3yrs | US$453.50k | 0.0070% $ 487.8k | |
| Independent Chairperson of the Board | 18.8yrs | US$431.12k | 0.16% $ 10.9m | |
| Independent Director | 4yrs | US$287.84k | 0.0050% $ 347.4k | |
| Member of Scientific Advisory Board | 8.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board & Independent Director | 8.3yrs | US$282.84k | 0.00096% $ 66.7k | |
| Member of Scientific Advisory Board | 8.3yrs | データなし | データなし | |
| Independent Director | 4.3yrs | US$287.84k | 0.0042% $ 291.8k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 10yrs | US$307.84k | 0.0071% $ 493.3k |
8.3yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: RGENの 取締役会 は 経験豊富 であると考えられます ( 8.3年の平均在任期間)。